Answers are grounded in this paper and cite their sources.
Case presentation reveals growth hormone and thyroid hormone deficiencies in a child after Lu-DOTATATE therapy, suggesting screening is needed.
Objectives Treatment for neuroblastoma with chemotherapy and [ 131 I]MIBG can induce endocrine adverse effects, including thyroid disorders, gonadal insufficiency or short stature. Neuroblastoma can also be targeted at the somatostatin receptor, using [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy. Thus far no endocrine effects have been reported after [ 177 Lu]Lu-DOTATATE treatment in children. Case presentation We report a first case of pituitary dysfunction, reflected as growth hormone deficiency and central hypothyroidism, following treatment with [ 177 Lu]Lu-DOTATATE for refractory neuroblastoma. Conclusions We hypothesize that the GH and TSH deficiency in this case are caused by pituitary damage through binding of [ 177 Lu]Lu-DOTATATE to the somatostatin receptors in the pituitary gland. If [ 177 Lu]Lu-DOTATATE in the future becomes a more upfront treatment we strongly underline screening on pituitary dysfunction after exposure to [ 177 Lu]Lu-DOTATATE in childhood.
No takes yet. Share an insight, caveat, or question.
Wessel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: